Transcript Document

Driving the Transition to Individualized Cancer
Treatment by Addressing Critical Questions
Genomic Health Has Provided It’s Oncotype DX Breast,
Colon, and Prostate Cancer Tests to Help More Than
350,000 Patients
1
Do I need
chemotherapy?
Do I need
radiation?
Do I have
aggressive
disease?
Do I need
surgery?
INVASIVE
BREAST CANCER
DCIS
BREAST CANCER
STAGE II/III
COLON CANCER
PROSTATE CANCER
Oncotype DX Changed Treatment Decisions in Over One-Third
of Breast Cancer Patients Leading to Less Toxicity and
Healthcare Costs
Treatment
Plan After
Prior
toBreast
Oncotype
Women
Diagnosed
withOncotype
Cancer
DXDX
• •Chemotherapy
recommended
for 62%Decisions
of patients
Over a 37% Change
in Treatment
Do I need
chemotherapy?
INVASIVE
BREAST CANCER
Chemotherapy
No Chemotherapy
* Based on meta-analysis of seven studies with 912 patients
2
Accurate Prediction of Prostate Cancer Risk is
Needed at Time of Biopsy
Do I need
surgery?
PROSTATE CANCER
3
Oncotype DX Genomic Prostate Score Provides
Significant Clinical Advantages and Actionable
Information
Prostate Clinical Validation Study
(American Urological Association
Meeting May 2013)
"These results have the potential
to change medical practice
significantly by providing
physicians and their patients with
a multi-gene prostate cancer test,
designed specifically for biopsies,
that will improve treatment
decisions for early-stage prostate
cancer at the time of diagnosis.”
— Peter Carroll, M.D., M.P.H.
Chair, Department of Urology,
University of California, San Francisco
and Lead Investigator
4
• Optimized technology to
analyze tiny needle biopsies
• Identified genes that predict
disease aggressiveness and
address tumor heterogeneity
• Established multiple biological
pathways are highly significant
• Studied relevant patient
populations
• Developed to answer critical
treatment questions prior to
intervention